Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Neuronetics, Inc. STIM
$2.81
+$0.07 (2.37%)
На 18:01, 12 мая 2023
+184.70%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
78566618.00000000
-
week52high
6.95
-
week52low
2.01
-
Revenue
65206000
-
P/E TTM
-2
-
Beta
1.94310500
-
EPS
-1.35000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 12:30
Описание компании
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| JMP Securities | Market Outperform | Market Outperform | 14 окт 2021 г. |
| BTIG | Neutral | Buy | 13 окт 2021 г. |
| William Blair | Outperform | Market Perform | 22 янв 2021 г. |
| Canaccord Genuity | Buy | Buy | 26 окт 2020 г. |
| BTIG | Buy | 06 окт 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| MACAN WILLIAM ANDREW | D | 338719 | 16046 | 23 янв 2023 г. |
| CANNELL CAPITAL LLC | D | 2939329 | 2912 | 17 янв 2023 г. |
| Furlong Stephen | D | 373269 | 16050 | 17 янв 2023 г. |
| CANNELL CAPITAL LLC | D | 2942241 | 4896 | 13 янв 2023 г. |
| CANNELL CAPITAL LLC | D | 2947137 | 12397 | 12 янв 2023 г. |
| CANNELL CAPITAL LLC | D | 2959534 | 8970 | 11 янв 2023 г. |
| CANNELL CAPITAL LLC | D | 2968504 | 36885 | 10 янв 2023 г. |
| CANNELL CAPITAL LLC | D | 3005389 | 141664 | 09 янв 2023 г. |
| CANNELL CAPITAL LLC | D | 3147053 | 25937 | 06 янв 2023 г. |
| CANNELL CAPITAL LLC | D | 3172990 | 33267 | 05 янв 2023 г. |
Новостная лента
Neuronetics to Present at the JMP Securities Life Sciences Conference
GlobeNewsWire
09 мая 2023 г. в 17:00
MALVERN, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “company” or Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, that Keith Sullivan, President and Chief Executive Officer, and Steve Furlong, Senior Vice President, Chief Financial Officer, and Treasurer will present at the JMP Securities Life Sciences on Tuesday, May 16, 2023. The Company is scheduled to present at 12:30 pm Eastern Time the same day via webcast.
Neuronetics to Report First Quarter 2023 Financial and Operating Results and Host Conference Call
GlobeNewsWire
25 апр 2023 г. в 08:30
MALVERN, Pa., April 25, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release first quarter 2023 financial and operating results prior to market open on Tuesday, May 9th, 2023. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
Cannell Capital Now Owns 11.03% of Neuronetics
24/7 Wall Street
23 мар 2023 г. в 22:21
Fintel reports that Cannell Capital has filed a 13D/A form with the SEC disclosing ownership of 3.13MM shares of Neuronetics Inc (STIM).
Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
07 мар 2023 г. в 09:47
Neuronetics (STIM) delivered earnings and revenue surprises of 30.23% and 9.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics to Report Fourth Quarter 2022 Financial and Operating Results and Host Conference Call
GlobeNewsWire
22 февр 2023 г. в 16:35
MALVERN, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release fourth quarter 2022 financial and operating results prior to market open on Tuesday, March 7th, 2023. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.